Sopharma AD (SPH) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sopharma AD (SPH) has a cash flow conversion efficiency ratio of -0.019x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (zł-17.24 Million ≈ $-4.74 Million USD) by net assets (zł926.37 Million ≈ $254.95 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Sopharma AD for the company's overall valuation and market capitalisation.
Sopharma AD - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Sopharma AD's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Sopharma AD Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sopharma AD ranked by their cash flow conversion efficiency. Explore SPH cash to earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Nanobiotix S.A
PA:NANO
|
0.253x |
|
China Yuchai International Limited
F:CYD
|
N/A |
|
Hunan Valin Wire & Cable Co Ltd
SHE:001208
|
-0.004x |
|
Wuxi Best Precision Machinery Co Ltd
SHE:300580
|
0.036x |
|
Mitra Adiperkasa Tbk
JK:MAPI
|
0.124x |
|
Max Stock Ltd
TA:MAXO
|
0.203x |
|
Dalian Dalicap Technology Co Ltd
SHE:301566
|
N/A |
|
Shenzhen Zhenye Group Co Ltd
SHE:000006
|
-0.037x |
Annual Cash Flow Conversion Efficiency for Sopharma AD (2011–2024)
The table below shows the annual cash flow conversion efficiency of Sopharma AD from 2011 to 2024. View latest Sopharma AD stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | zł843.10 Million ≈ $232.03 Million |
zł76.73 Million ≈ $21.12 Million |
0.091x | +52.30% |
| 2023-12-31 | zł753.63 Million ≈ $207.41 Million |
zł45.03 Million ≈ $12.39 Million |
0.060x | -65.57% |
| 2022-12-31 | zł718.13 Million ≈ $197.64 Million |
zł124.62 Million ≈ $34.30 Million |
0.174x | +250.52% |
| 2021-12-31 | zł658.87 Million ≈ $181.33 Million |
zł-75.96 Million ≈ $-20.91 Million |
-0.115x | +63.59% |
| 2020-12-31 | zł566.60 Million ≈ $155.94 Million |
zł-179.41 Million ≈ $-49.38 Million |
-0.317x | -41.94% |
| 2019-12-31 | zł575.77 Million ≈ $158.46 Million |
zł-128.44 Million ≈ $-35.35 Million |
-0.223x | -500.25% |
| 2018-12-31 | zł508.53 Million ≈ $139.95 Million |
zł28.34 Million ≈ $7.80 Million |
0.056x | -29.89% |
| 2017-12-31 | zł503.11 Million ≈ $138.46 Million |
zł40.00 Million ≈ $11.01 Million |
0.080x | -22.88% |
| 2016-12-31 | zł491.22 Million ≈ $135.19 Million |
zł50.64 Million ≈ $13.94 Million |
0.103x | +121.34% |
| 2015-12-31 | zł457.64 Million ≈ $125.95 Million |
zł21.31 Million ≈ $5.87 Million |
0.047x | -0.37% |
| 2014-12-31 | zł431.64 Million ≈ $118.79 Million |
zł20.18 Million ≈ $5.55 Million |
0.047x | -34.03% |
| 2013-12-31 | zł412.77 Million ≈ $113.60 Million |
zł29.25 Million ≈ $8.05 Million |
0.071x | -21.21% |
| 2012-12-31 | zł391.35 Million ≈ $107.71 Million |
zł35.20 Million ≈ $9.69 Million |
0.090x | -14.33% |
| 2011-12-31 | zł365.81 Million ≈ $100.68 Million |
zł38.40 Million ≈ $10.57 Million |
0.105x | -- |
About Sopharma AD
Sopharma AD produces, distributes, and exports pharmaceutical products in Europe, Bulgaria, and internationally. It offers Carsil to treat liver disease; Tempalgin, a painkiller; Analgin, a pain reliever; Tabex, a drug used for smoking secession; Tribestan, a drug used for stimulation of the male reproductive system; Broncholytin, which is used to suppress cough; Nivalin for use in the peripheral… Read more